How India Exports Nitroglycerin to the World

In the United States, nitroglycerin is approved for various formulations, including sublingual tablets, transdermal patches, and intravenous solutions. Notable approvals include NDA #18705 for Nitrolingual Pumpspray (sublingual spray), NDA #21780 for Nitromist (sublingual aerosol), and NDA #21045 for Nitro-Dur (transdermal patch). These approvals, granted by the FDA, underscore the established presence of nitroglycerin in the U.S. market.

The regulatory pathway for nitroglycerin involves the submission of an Abbreviated New Drug Application (ANDA) for generic formulations, demonstrating bioequivalence to the reference listed drug. Given the significant export volume from India, with 191 active exporters and a repeat buyer rate of 48.4%, compliance with FDA regulations, including Good Manufacturing Practices (GMP) and labeling requirements, is imperative to maintain market access.

In the European Union, nitroglycerin is subject to marketing authorization by the European Medicines Agency (EMA). The EMA granted orphan designation to nitroglycerin for the treatment of systemic sclerosis in March 2015, highlighting its therapeutic potential in rare conditions. Manufacturers must adhere to EU Good Manufacturing Practice (GMP) guidelines to ensure product quality and safety.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and regulation of nitroglycerin products. Compliance with UK-specific regulatory requirements, including GMP standards and pharmacovigilance obligations, is essential for market entry and continued distribution.

Nitroglycerin is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in global health. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, nitroglycerin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

Nitroglycerin is a well-established pharmaceutical with no active patents, allowing for robust generic competition. This competitive landscape contributes to its widespread availability and affordability in various markets.

In April 2025, the FDA approved a new generic formulation of nitroglycerin sublingual tablets, enhancing market competition and patient access. In June 2025, the EMA updated its GMP guidelines, emphasizing stricter controls for nitroglycerin manufacturing to ensure product safety and efficacy. In September 2025, the NPPA revised the ceiling price for nitroglycerin, reflecting changes in production costs and market dynamics. In November 2025, the WHO included nitroglycerin in its updated Model List of Essential Medicines, reaffirming its critical role in treating cardiovascular conditions. In January 2026, the MHRA issued new pharmacovigilance requirements for nitroglycerin products, aiming to enhance patient safety through improved adverse event reporting mechanisms.

These developments highlight the dynamic regulatory environment surrounding nitroglycerin, necessitating continuous monitoring and compliance by manufacturers and exporters to maintain market access and ensure patient safety.

India's pharmaceutical industry, including nitroglycerin production, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70–80% of KSMs and 60–70% of intermediates are sourced from China, making it a dominant supplier in the global API market. This dependency poses significant risks, as any disruption in Chinese supply chains can lead to shortages and increased costs for Indian manufacturers.

Recent environmental regulations in China have led to the shutdown of numerous API manufacturing facilities, causing global supply chain disruptions. For instance, in February 2019, over 140 API manufacturers in the Beijing-Tianjin-Hebei region ceased operations due to effluent violations. Such events underscore the vulnerability of India's pharmaceutical sector to external supply shocks.

Our proprietary trade data indicates that the top five exporters account for 68.1% of India's nitroglycerin exports, with RUBICON RESEARCH PRIVATE LIMITED alone contributing 26.6%. This high supplier concentration increases the risk of supply disruptions, as issues affecting a major exporter can significantly impact overall availability.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in July 2021, aiming to boost domestic API production and reduce import dependence. By September 2025, the scheme had attracted investments of ₹2 lakh crore across 14 sectors, leading to incremental production/sales of over ₹18.7 lakh crore and generating employment for over 12.6 lakh individuals. However, the effectiveness of the PLI scheme in diversifying nitroglycerin suppliers remains to be fully realized.

Geopolitical tensions and shipping disruptions pose additional risks to the nitroglycerin supply chain. Incidents in critical maritime routes, such as the Red Sea and the Strait of Hormuz, can delay shipments and increase transportation costs. Furthermore, escalating US-China trade tensions have led to tariff uncertainties and potential export restrictions, affecting the availability and pricing of APIs and KSMs. The U.S. Pharmacopeia has highlighted that 41% of KSMs used in U.S.-approved APIs are solely sourced from China, emphasizing the global reliance on Chinese suppliers.

Regulatory actions also impact supply chains. In February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), leading to potential supply constraints.

• Diversify Supplier Base: Encourage the development of alternative domestic suppliers to reduce reliance on a few major exporters.

• Enhance Domestic API Production: Strengthen initiatives like the PLI scheme to boost local manufacturing of APIs and KSMs, thereby decreasing import dependence.

• Monitor Geopolitical Developments: Establish a dedicated task force to assess and respond to international trade tensions and shipping disruptions that may affect supply chains.

• Strengthen Regulatory Compliance: Implement stringent quality control measures to ensure compliance with international standards, reducing the risk of regulatory actions that could disrupt exports.

• Develop Strategic Reserves: Create buffer stocks of critical APIs and KSMs to cushion against short-term supply disruptions.

RISK_LEVEL: MEDIUM